Beijing Hotgen Biotech Co Ltd
SSE:688068
Beijing Hotgen Biotech Co Ltd
Total Equity
Beijing Hotgen Biotech Co Ltd
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
Total Equity
¥3.4B
|
CAGR 3-Years
65%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Total Equity
¥55.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Total Equity
¥12.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Total Equity
¥40.3B
|
CAGR 3-Years
25%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Total Equity
¥21B
|
CAGR 3-Years
9%
|
CAGR 5-Years
50%
|
CAGR 10-Years
39%
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Total Equity
¥9.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Beijing Hotgen Biotech Co Ltd's Total Equity?
Total Equity
3.4B
CNY
Based on the financial report for Dec 31, 2023, Beijing Hotgen Biotech Co Ltd's Total Equity amounts to 3.4B CNY.
What is Beijing Hotgen Biotech Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
74%
Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Beijing Hotgen Biotech Co Ltd have been 65% over the past three years , 74% over the past five years .